TPS Treatment for Parkinson’s disease

Transcranial Pulse Stimulation (TPS) – Indication: Parkinson’s disease

Parkinson’s disease is the second most common neurodegenerative disease, which is mainly characterized by the loss of dopamine-producing neurons in a specific brain region, the substantia nigra. This loss leads to a lack of dopamine, which causes motor symptoms such as tremor, muscle stiffness (rigor), slow movements (bradykinesia) and postural instability. In addition to the motor symptoms, non-motor symptoms can also occur, including sleep disturbances, depression, cognitive impairment and autonomic dysfunction.

The exact causes of the disease are not yet fully understood, but genetic and environmental factors are thought to play a role. Treatment of Parkinson’s disease focuses on alleviating symptoms, often through medication that increases dopamine levels or mimics its effects, physical therapies and now deep brain stimulation (DBS), although this is a surgical procedure. The disease usually progresses over time and there is currently no cure.

TPS Treatment for Parkinson’s disease: Goals and possibilities of TPS therapy

In the context of TPS research and development, Parkinson’s disease has been a core indication for many years and clinical trials have been in progress for several years. Long-term observations now document the treatment of Parkinson’s patients over a period of more than a decade. Improvements in symptoms and general condition are frequently seen in most of the patients treated and, according to survey results in clinics and practices, around 80 percent of those affected benefit from TPS. This is particularly true for this indication in moderate and severe stages of the disease (see also: Significant study results for Parkinson’s).